Author:
Taranukha Tatyana,Kounev Venelin
Publisher
Springer International Publishing
Reference24 articles.
1. Lada O, Benhamou Y, Poynard T, Thibault V. Coexistance of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of “a” determinant variants. J Virol. 2006;80(6):2968–75.
2. Galati G, Vincentis A, Vespasiani-Gentilucci U, Gallo P, Vincenti D, Solmone M, et al. Coexistance of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination. BMC Gastroenterol. 2014;14(94):1–4.
3. Colson P, Borentain P, Motte A, Henry M, Moal V, Botta-Fridlund D, et al. Clinical and virological significance of the co-existance of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers. Virology. 2007;367:30–40.
4. Hoofnagle J, Doo E, Liang J, Fleischer R, Lok A. Management of hepatitis B; summary of clinical research workshop. Hepatology. 2007;45(4):1056–75.
5. Reddy K, Beavers K, Hammond S, Lim J, Falck-Ytter Y. American Gastroenterological Association Institute Guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppresive drug therapy. Gastroenterology. 2015;148(1):215–9.